Mario Stevenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mario Stevenson has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Mark Sharkey
Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136
4 shared publications- Javier Martinez-Picado
IrsiCaixa, Badalona, Spain
3 shared publications - Alain Lafeuillade
General Hospital , Toulon , France
2 shared publications Anuska Llano
Hospital Universitari Germans Trias I Pujol, Badalona, Spain
2 shared publications- Carla Mavian
Centre for Epidemic Response and Innovation (CERI) School of Data Science and Computational Thinking, Stellenbosch University Stellenbosch South Africa
2 shared publications Christian Brander
Hospital Universitari Germans Trias I Pujol, Badalona, Spain
2 shared publications
Latest Publications
- Open Access
Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill
In the pursuit of an HIV cure, elimination of persistent HIV reservoirs requires strategies that promote immune-mediated or cytopathic clearance of infected cells. While many such approaches are being developed against infected CD4+ T cells, HIV-infected macrophages are comparatively resistant to cell death and to several killing mechanisms being explored for T-cell reservoirs, highlighting the need for strategies that specifically eliminate this reservoir. Targeted Activator of Cell Kill (TACK), developed by Merck Pharmaceuticals, are non-nucleoside reverse transcriptase inhibitor-derived molecules designed to selectively kill HIV-1-infected cells by inducing premature activation of the viral protease. Here, we evaluated the TACK compounds Pyr01 and it?s inactive analog Pyr02, in primary human monocyte-derived macrophages (MDMs). Pyr01 had minimal effects on uninfected MDM viability but potently targeted HIV-1-infected MDMs, with an EC?? of approximately 0.36 ?M. Pyr01 treatment produced a rapid and sustained reduction in extracellular virion-associated HIV-1 RNA and significantly decreased cell-associated viral RNA, whereas Pyr02 exhibited minimal activity. Immunofluorescence microscopy and live-cell imaging further demonstrated a marked loss of HIV-1-infected macrophages following Pyr01 treatment, consistent with selective elimination of infected cells. These findings identify Pyr01 as a specific mediator of HIV-infected macrophage death and establish premature viral protease activation as a strategy for overcoming the intrinsic resistance of macrophage reservoirs to clearance. Targeting this macrophage-specific barrier may complement approaches directed at CD4+ T-cell reservoirs and broaden the cellular reach of HIV cure strategies.
Open AccessSelective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill
In the pursuit of an HIV cure, elimination of persistent HIV reservoirs requires strategies that promote immune-mediated or cytopathic clearance of infected cells. While many such approaches are being developed against infected CD4+ T cells, HIV-infected macrophages are comparatively resistant to cell death and to several killing mechanisms being explored for T-cell reservoirs, highlighting the need for strategies that specifically eliminate this reservoir. Targeted Activator of Cell Kill (TACK), developed by Merck Pharmaceuticals, are non-nucleoside reverse transcriptase inhibitor-derived molecules designed to selectively kill HIV-1-infected cells by inducing premature activation of the viral protease. Here, we evaluated the TACK compounds Pyr01 and it?s inactive analog Pyr02, in primary human monocyte-derived macrophages (MDMs). Pyr01 had minimal effects on uninfected MDM viability but potently targeted HIV-1-infected MDMs, with an EC?? of approximately 0.36 ?M. Pyr01 treatment produced a rapid and sustained reduction in extracellular virion-associated HIV-1 RNA and significantly decreased cell-associated viral RNA, whereas Pyr02 exhibited minimal activity. Immunofluorescence microscopy and live-cell imaging further demonstrated a marked loss of HIV-1-infected macrophages following Pyr01 treatment, consistent with selective elimination of infected cells. These findings identify Pyr01 as a specific mediator of HIV-infected macrophage death and establish premature viral protease activation as a strategy for overcoming the intrinsic resistance of macrophage reservoirs to clearance. Targeting this macrophage-specific barrier may complement approaches directed at CD4+ T-cell reservoirs and broaden the cellular reach of HIV cure strategies.
- 1 March 2026
- Published by International Antiviral Society - USA in Topics in Antiviral Medicine
- Vol. 34 (2) , 437-448
Basic Science Highlights From the 2026 Conference on Retroviruses and Opportunistic Infections
The 2026 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado, showcased major advances in our understanding of HIV replication, viral persistence, host-virus interactions, and innate immune sensing. Basic science presentations emphasized the remarkable complexity of the HIV replication cycle and highlighted how structural virology, systems biology, and genome-wide screening approaches are transforming the field. A consistent highlight of the conference is the Scott M. Hammer workshop for new investigators and trainees in which scientific experts help orient trainees to thematic areas being covered in the conference. This underscores the conference's dedication to the mentoring and training of early career investigators new to the field of HIV/AIDS research.
- 1 March 2026
- Published by International Antiviral Society - USA in Topics in Antiviral Medicine
- Vol. 34 (2) , 437-448
Basic Science Highlights From the 2026 Conference on Retroviruses and Opportunistic Infections
The 2026 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado, showcased major advances in our understanding of HIV replication, viral persistence, host-virus interactions, and innate immune sensing. Basic science presentations emphasized the remarkable complexity of the HIV replication cycle and highlighted how structural virology, systems biology, and genome-wide screening approaches are transforming the field. A consistent highlight of the conference is the Scott M. Hammer workshop for new investigators and trainees in which scientific experts help orient trainees to thematic areas being covered in the conference. This underscores the conference's dedication to the mentoring and training of early career investigators new to the field of HIV/AIDS research.
- 1 June 2025
- Published by International Antiviral Society - USA in Topics in Antiviral Medicine
- Vol. 33 (3) , 539-554
CROI 2025: Summary of Basic Science Research in HIV
The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco maintained its existing format with a combination of plenary lectures, workshops, oral and poster abstract sessions, themed discussions, and interactive symposia to deliver the latest advances in HIV/AIDS research to the approximately 4000 delegates in attendance. The conference featured a comprehensive collection of presentations addressing the molecular biology of HIV-1, with the basic virology track offering mechanistic insights into viral replication, immune evasion, and host-pathogen interactions. CROI showcased a range of innovative approaches to decipher and target the latent reservoir. From high-resolution lineage tracking in nonhuman primates to dissection of chromatin landscapes and latency regulatory circuits, studies presented at this year's meeting underscored the complexity of HIV persistence and the need for multidimensional intervention strategies. Selected abstracts are high-lighted, emphasizing mechanistic insights, methodologic innovations, and therapeutic implications. As with prior renditions of the conference, CROI continues to set the standard for engagement of early career investigators. Sessions such as the Scott M. Hammer Workshop for New Investigators and Trainees provide an effective forum for orientation to the various thematic areas covered at CROI.
- 1 June 2025
- Published by International Antiviral Society - USA in Topics in Antiviral Medicine
- Vol. 33 (3) , 539-554
CROI 2025: Summary of Basic Science Research in HIV
The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco maintained its existing format with a combination of plenary lectures, workshops, oral and poster abstract sessions, themed discussions, and interactive symposia to deliver the latest advances in HIV/AIDS research to the approximately 4000 delegates in attendance. The conference featured a comprehensive collection of presentations addressing the molecular biology of HIV-1, with the basic virology track offering mechanistic insights into viral replication, immune evasion, and host-pathogen interactions. CROI showcased a range of innovative approaches to decipher and target the latent reservoir. From high-resolution lineage tracking in nonhuman primates to dissection of chromatin landscapes and latency regulatory circuits, studies presented at this year's meeting underscored the complexity of HIV persistence and the need for multidimensional intervention strategies. Selected abstracts are high-lighted, emphasizing mechanistic insights, methodologic innovations, and therapeutic implications. As with prior renditions of the conference, CROI continues to set the standard for engagement of early career investigators. Sessions such as the Scott M. Hammer Workshop for New Investigators and Trainees provide an effective forum for orientation to the various thematic areas covered at CROI.
- Open Access
- 23 August 2024
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 11 (4) , 209-219
Myeloid Cell Reservoirs: Role in HIV-Host Interplay and Strategies for Myeloid Reservoir Elimination
Purpose of Review: Despite host antiviral responses and antiretroviral therapy, HIV-1 continues to persist in myeloid cell reservoirs. Hence, strategies that promote the elimination of myeloid reservoirs are critically needed. Insight into host-HIV interactions is key to achieving a cure. Recent Findings: Host antiviral factors are often antagonized by HIV proteins that help establish infection while promoting chronic inflammation and disease in the host. Currently, several methods to eliminate the virus are under investigation including broadly neutralizing antibodies, latency reversal agents, CRISPR platforms, and immune modulation. Compounds that can penetrate the blood brain barrier are also being developed for reservoir cell clearance. Summary: Here, we will outline features of myeloid cell biology and host-virus interactions that facilitate HIV persistence. We will also review current therapeutic strategies and potential drug candidates to cure HIV infection of myeloid cells even in difficult-to-treat tissues such as the central nervous system.
- 23 August 2024
- Published by Springer Nature in Current Clinical Microbiology Reports
- Vol. 11 (4) , 209-219
Open AccessMyeloid Cell Reservoirs: Role in HIV-Host Interplay and Strategies for Myeloid Reservoir Elimination
Purpose of Review: Despite host antiviral responses and antiretroviral therapy, HIV-1 continues to persist in myeloid cell reservoirs. Hence, strategies that promote the elimination of myeloid reservoirs are critically needed. Insight into host-HIV interactions is key to achieving a cure. Recent Findings: Host antiviral factors are often antagonized by HIV proteins that help establish infection while promoting chronic inflammation and disease in the host. Currently, several methods to eliminate the virus are under investigation including broadly neutralizing antibodies, latency reversal agents, CRISPR platforms, and immune modulation. Compounds that can penetrate the blood brain barrier are also being developed for reservoir cell clearance. Summary: Here, we will outline features of myeloid cell biology and host-virus interactions that facilitate HIV persistence. We will also review current therapeutic strategies and potential drug candidates to cure HIV infection of myeloid cells even in difficult-to-treat tissues such as the central nervous system.
- Open Access
Help or Hinder: Protein Host Factors That Impact HIV-1 Replication
Interactions between human immunodeficiency virus type 1 (HIV-1) and the host factors or restriction factors of its target cells determine the cell’s susceptibility to, and outcome of, infection. Factors intrinsic to the cell are involved at every step of the HIV-1 replication cycle, contributing to productive infection and replication, or severely attenuating the chances of success. Furthermore, factors unique to certain cell types contribute to the differences in infection between these cell types. Understanding the involvement of these factors in HIV-1 infection is a key requirement for the development of anti-HIV-1 therapies. As the list of factors grows, and the dynamic interactions between these factors and the virus are elucidated, comprehensive and up-to-date summaries that recount the knowledge gathered after decades of research are beneficial to the field, displaying what is known so that researchers can build off the groundwork of others to investigate what is unknown. Herein, we aim to provide a review focusing on protein host factors, both well-known and relatively new, that impact HIV-1 replication in a positive or negative manner at each stage of the replication cycle, highlighting factors unique to the various HIV-1 target cell types where appropriate.
Open AccessHelp or Hinder: Protein Host Factors That Impact HIV-1 Replication
Interactions between human immunodeficiency virus type 1 (HIV-1) and the host factors or restriction factors of its target cells determine the cell’s susceptibility to, and outcome of, infection. Factors intrinsic to the cell are involved at every step of the HIV-1 replication cycle, contributing to productive infection and replication, or severely attenuating the chances of success. Furthermore, factors unique to certain cell types contribute to the differences in infection between these cell types. Understanding the involvement of these factors in HIV-1 infection is a key requirement for the development of anti-HIV-1 therapies. As the list of factors grows, and the dynamic interactions between these factors and the virus are elucidated, comprehensive and up-to-date summaries that recount the knowledge gathered after decades of research are beneficial to the field, displaying what is known so that researchers can build off the groundwork of others to investigate what is unknown. Herein, we aim to provide a review focusing on protein host factors, both well-known and relatively new, that impact HIV-1 replication in a positive or negative manner at each stage of the replication cycle, highlighting factors unique to the various HIV-1 target cell types where appropriate.
- Open Access
- 25 July 2024
- Published by MDPI AG in Preprints.org
Help or Hinder: Protein Host Factors That Impact HIV-1 Replication
Interactions between human immunodeficiency virus type 1 (HIV-1) and the host factors or restriction factors of its target cells determine the cell’s susceptibility to, and outcome of, infection. Factors intrinsic to the cell are involved at every step of HIV-1’s replication cycle, contributing to productive infection and replication, or severely attenuating HIV-1’s chances of success. Furthermore, factors unique to certain cell types contribute to the differences in infection between these cell types. Understanding the involvement of these factors in HIV-1 infection is a key requirement for the development of anti-HIV-1 therapies. As the list of factors grows, and the dynamic interactions between these factors and the virus are elucidated, comprehensive and up-to-date summaries that recount the knowledge gathered after decades of research are beneficial to the field, displaying what is known so that researchers can build off the groundwork of others to investigate what is unknown. Herein, we aim to provide a review focusing on protein host factors, both well-known and relatively new, that impact HIV-1 replication in a positive or negative manner at each stage of the replication cycle, highlighting factors unique to HIV-1’s various target cell types where appropriate.
- 25 July 2024
- Published by MDPI AG in Preprints.org
Open AccessHelp or Hinder: Protein Host Factors That Impact HIV-1 Replication
Interactions between human immunodeficiency virus type 1 (HIV-1) and the host factors or restriction factors of its target cells determine the cell’s susceptibility to, and outcome of, infection. Factors intrinsic to the cell are involved at every step of HIV-1’s replication cycle, contributing to productive infection and replication, or severely attenuating HIV-1’s chances of success. Furthermore, factors unique to certain cell types contribute to the differences in infection between these cell types. Understanding the involvement of these factors in HIV-1 infection is a key requirement for the development of anti-HIV-1 therapies. As the list of factors grows, and the dynamic interactions between these factors and the virus are elucidated, comprehensive and up-to-date summaries that recount the knowledge gathered after decades of research are beneficial to the field, displaying what is known so that researchers can build off the groundwork of others to investigate what is unknown. Herein, we aim to provide a review focusing on protein host factors, both well-known and relatively new, that impact HIV-1 replication in a positive or negative manner at each stage of the replication cycle, highlighting factors unique to HIV-1’s various target cell types where appropriate.
- 1 June 2024
- Vol. 32 (3) , 483-491
CROI 2024: Summary of Basic Science Research in HIV
Scientists from around the world gathered in Denver for the Conference on Retroviruses and Opportunistic Infections (CROI). The conference maintained its existing format and used a combination of plenary lectures, workshops, oral abstract sessions, themed discussions, and interactive symposia to deliver the latest advances in HIV/AIDS research to the almost 4000 delegates in attendance. As with previous CROI meetings, the conference provided a fertile environment for early-stage investigators who were interested in getting updates in areas of research outside of their particular domain. This was exemplified by the Scott M. Hammer Workshop for New Investigators and Trainees. Here, leading investigators helped orient new investigators and trainees to the various scientific presentations in the different thematic areas being covered at CROI. The meeting organizers did a great job of minimizing conflicts and made sure that talks in similar thematic areas would not end up in parallel sessions. The conference continues to focus on research related to HIV/AIDS and comorbidities. Approximately 20% of the accepted abstracts featured research on SARS-CoV-2 and 3% on mpox. CROI continues to serve as a “1-stop-shop” conference to educate and update infectious disease researchers on the latest developments in the field.
- 1 June 2024
- Vol. 32 (3) , 483-491
CROI 2024: Summary of Basic Science Research in HIV
Scientists from around the world gathered in Denver for the Conference on Retroviruses and Opportunistic Infections (CROI). The conference maintained its existing format and used a combination of plenary lectures, workshops, oral abstract sessions, themed discussions, and interactive symposia to deliver the latest advances in HIV/AIDS research to the almost 4000 delegates in attendance. As with previous CROI meetings, the conference provided a fertile environment for early-stage investigators who were interested in getting updates in areas of research outside of their particular domain. This was exemplified by the Scott M. Hammer Workshop for New Investigators and Trainees. Here, leading investigators helped orient new investigators and trainees to the various scientific presentations in the different thematic areas being covered at CROI. The meeting organizers did a great job of minimizing conflicts and made sure that talks in similar thematic areas would not end up in parallel sessions. The conference continues to focus on research related to HIV/AIDS and comorbidities. Approximately 20% of the accepted abstracts featured research on SARS-CoV-2 and 3% on mpox. CROI continues to serve as a “1-stop-shop” conference to educate and update infectious disease researchers on the latest developments in the field.
- 1 June 2023
- Vol. 31 (4) , 523-528
CROI 2023: Summary of Basic Science Research in HIV
The 2023 Conference on Retroviruses and Opportunistic Infections (CROI) represented the first fully in-person conference since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic began. CROI continues as the premier conference in which delegates can appraise themselves of almost every facet of HIV/AIDS research as well as emerging and re-emerging pathogens such as SARS-CoV-2 and mpox. The return to an in-person format is particularly important for early-stage investigators, who were faced with challenges of advancing their independent research careers during the SARS-CoV-2 pandemic. The personnel interactions and face-to-face meetings between junior investigators and their peers enable collaboration that is important in the academic development process. A very packed program showcased research advances in basic research, clinical, and epidemiology/public health endeavors around HIV and other pandemic viruses. Session presentation summaries, themed discussion sessions, and scientific workshops condense and assimilate specific areas of research that are particularly useful for delegates who want to see the state of research in areas that may be outside their specific areas of interest. The conference organizers drew on more than 1000 accepted abstracts to assemble a dynamic and engaging program that was appealing to infectious disease researchers worldwide.
- 1 June 2023
- Vol. 31 (4) , 523-528
CROI 2023: Summary of Basic Science Research in HIV
The 2023 Conference on Retroviruses and Opportunistic Infections (CROI) represented the first fully in-person conference since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic began. CROI continues as the premier conference in which delegates can appraise themselves of almost every facet of HIV/AIDS research as well as emerging and re-emerging pathogens such as SARS-CoV-2 and mpox. The return to an in-person format is particularly important for early-stage investigators, who were faced with challenges of advancing their independent research careers during the SARS-CoV-2 pandemic. The personnel interactions and face-to-face meetings between junior investigators and their peers enable collaboration that is important in the academic development process. A very packed program showcased research advances in basic research, clinical, and epidemiology/public health endeavors around HIV and other pandemic viruses. Session presentation summaries, themed discussion sessions, and scientific workshops condense and assimilate specific areas of research that are particularly useful for delegates who want to see the state of research in areas that may be outside their specific areas of interest. The conference organizers drew on more than 1000 accepted abstracts to assemble a dynamic and engaging program that was appealing to infectious disease researchers worldwide.
- Open Access
- 31 August 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (4) , e0135322
Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells
Even with effective ART, HIV-1 persists at undetectable levels and rebounds in individuals who stop treatment. Cellular and anatomical reservoirs ignite viral rebound upon treatment interruption, remaining one of the key obstacles for HIV-1 cure.
- 31 August 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (4) , e0135322
Open AccessDiscordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells
Even with effective ART, HIV-1 persists at undetectable levels and rebounds in individuals who stop treatment. Cellular and anatomical reservoirs ignite viral rebound upon treatment interruption, remaining one of the key obstacles for HIV-1 cure.
- 22 June 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (12) , e0048422
Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity
Although HIV-1 infection can be suppressed using antiretroviral therapy, it cannot yet be cured. This is because HIV-1 integrates itself into host cells and may become dormant but also remains ready to emerge from such reservoirs when antiretroviral therapy stops.
- 22 June 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (12) , e0048422
Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity
Although HIV-1 infection can be suppressed using antiretroviral therapy, it cannot yet be cured. This is because HIV-1 integrates itself into host cells and may become dormant but also remains ready to emerge from such reservoirs when antiretroviral therapy stops.